Creating Best-in-Class Multispecific Antibody Modalities

The multispecific antibodies stream at the PEGS Summit will take you through a review of constructs, engineering and platform developments all the way to the review of preclinical and clinical results. Newer platforms, innovative approaches, combination strategies and novel constructs are combining to yield unprecedented efficacy. Don’t miss the most significant forum of the year to hear about the latest advances in the industry and meet face-to-face with leaders who are changing the future of biologics. 

Conferences and Training Seminars Include:

May 13-14

Introduction to Multispecific Antibodies

May 14-15

Advancing Bispecific Antibodies and Combination Therapy to the Clinic

May 16-17

Engineering Bispecific Antibodies

Keynote Speakers Include:

Generating CD8-Selective T Cell Engager Molecules
Mark Cobbold, PhD, Vice President, Oncology Early Discovery, AstraZeneca Pharmaceuticals

Overcoming Tumor Heterogeneity by ex vivo Arming of T Cells Using Multiple Bispecific Antibodies
Nai-Kong V. Cheung, MD, PhD, Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center

2024 PROGRAMS

View By:

• Display of Biologics
• Engineering Antibodies
• Machine Learning for Protein Engineering

• Antibodies for Cancer Therapy
• Emerging Targets for Oncology
• Antibody Drug Conjugates

• TS: Intro to Bispecifics
• Advancing Bispecific Antibodies
• Engineering Bispecific Antibodies

• Advances in Immunotherapy
• Cell-Based Immunotherapy
• In vivo Cell and Gene Engineering

• Difficult-to-Express Proteins
• Optimizing Protein Expression
• Protein Production Workflows

• Digital Integration in Biotherapeutic Analytics
• Biophysical Methods
• Characterization for Novel Biotherapeutics

• TS: Intro to Immunogenicity
• Immunogenicity Assessment and Management
• TS: Intro to Bioassays

• Emerging Indications for Therapeutic Antibodies
• mRNA Therapeutics
• In vivo Cell and Gene Engineering